ArticleSurgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery2019
GLP-1 and PYY
Article in Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 27 citations in OpenAlex.
- Changes in Plasma Metabolomic Profile Following Bariatric Surgery, Lifestyle Intervention or Diet Restriction-Insights from Human and Rat Studies.International journal of molecular sciences · 2023Trial
- Global Trends in Research of Intestinal Cells and Type 2 Diabetes Mellitus: A Bibliometric and Visualized Analysis from 2004 to 2023.Endocrine, metabolic & immune disorders drug targets · 2026Review
- Fat taste responsiveness, but not dietary fat intake, is affected inbioRxiv : the preprint server for biology · 2025Article
- Role of curcumin in altering gut microbiota for anti-obesity and anti-hyperlipidemic effects.Frontiers in microbiology · 2025Review
- Effects of NPY-2 Receptor Antagonists, Semaglutide, PYYNutrients · 2024Article
- GLP-1 and PYY for the treatment of obesity: a pilot study on the use of agonists and antagonists in diet-induced rats.Endocrine connections · 2024Article
- Duodenal-Jejunal Bypass Restores Sweet Taste Receptor-Mediated Glucose Sensing and Absorption in Diabetic Rats.Journal of diabetes research · 2024Article
- Dietary Fat Modulation of Gut Microbiota and Impact on Regulatory Pathways Controlling Food Intake.Nutrients · 2023Review
- A peptide triple agonist of GLP-1, neuropeptide Y1, and neuropeptide Y2 receptors promotes glycemic control and weight loss.Scientific reports · 2023Article
- Gut-brain mechanisms underlying changes in disordered eating behaviour after bariatric surgery: a review.Reviews in endocrine & metabolic disorders · 2022Review
- Liraglutide + PYYJournal of clinical medicine · 2022Article
- Mechanisms of Weight Loss After Obesity Surgery.Endocrine reviews · 2022Review
- Article
- Gastrointestinal peptides in eating-related disorders.Physiology & behavior · 2021 · on this mapReview
- Leptin Receptors Are Not Required for Roux-en-Y Gastric Bypass Surgery to Normalize Energy and Glucose Homeostasis in Rats.Nutrients · 2021Article
- Simulating the Post-gastric Bypass Intestinal Microenvironment Uncovers a Barrier-Stabilizing Role for FXR.iScience · 2020Article
- Gastric bypass in female rats lowers concentrated sugar solution intake and preference without affecting brief-access licking after long-term sugar exposure.American journal of physiology. Regulatory, integrative and comparative physiology · 2020Article
- Toward a Medical Gastric Bypass: Chronic Feeding Studies With Liraglutide + PYYFrontiers in endocrinology · 2020Article
- Comment on: GLP-1 and PYYSurgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery · 2019Article
Corrections and comments
- Commented on by
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRoux-en-Y gastric bypass (RYGB) modifies various aspects of eating behavior in morbidly obese individuals to cause marked and lasting weight loss and improvements in metabolic health, but the underlying mechanisms remain poorly understood.
objectivesTo assess the relative contributions of the gut hormones glucagon-like peptide 1 (GLP-1) and peptide tyrosine tyrosine 3-36 (PYY
settingUniversity hospital, Würzburg, Germany.
methodsHF diet-induced obese male Wistar rats underwent RYGB (n = 11) or sham (n = 7) surgeries and were subsequently maintained on a choice of low-fat (10% calories from fat) and HF (60% calories from fat) diets. From postoperative weeks 4 to 6, acute feeding studies were performed in which the selective GLP-1 receptor antagonist exendin-9 (30 μg/kg), the second-generation selective Y2 receptor antagonist JNJ-31020028 (10 mg/kg), or a combination of both drugs was administered intraperitoneally.
resultsDuring the observational period weight, adiposity and total food intake were lower while postprandial plasma GLP-1 and peptide tyrosine tyrosine levels were higher for RYGB-operated compared with sham-operated rats. There was a gradual shift in preference from HF to low-fat food in RYGB-operated rats by postoperative week 3. Single antagonist treatments had a relatively modest impact on HF food preference in rats from both surgical groups. However, dual antagonist treatment caused a striking increase in HF food preference specifically in RYGB-operated rats.
conclusionsGLP-1 and peptide tyrosine tyrosine 3-36 reduce HF food preference additively after RYGB supporting the use of gut hormone combination strategies for healthier feeding behavior.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.